Oncogene · 2015 · 60 citations · 63 references
MedicineCancer BiologyOncologyCell SignalingMolecular OncologySignal TransductionB Cell RegulationCancer Cell SignalingCancer ProgressionHedgehog SignalingOncogenic Signaling PathwaysSignal Transduction In CancerCancer Signaling PathwaysEpigenetic Alterations In CarcinogenesisGli Transcription FactorsMalignant ProgressionPi3k-akt Signaling PathwaySignal Transduction Cross-talkTransgenic Mouse Cancer ModelsTransgenic Mouse Models
The initiation and maintenance of a malignant phenotype requires complex and synergistic interactions of multiple oncogenic signals. The Hedgehog (HH)/GLI pathway has been implicated in a variety of cancer entities and targeted pathway inhibition is of therapeutic relevance. Signal cross-talk with other cancer pathways including PI3K/AKT modulates HH/GLI signal strength and its oncogenicity. In this study, we addressed the role of HH/GLI and its putative interaction with the PI3K/AKT cascade in the initiation and maintenance of chronic lymphocytic leukemia (CLL). Using transgenic mouse models, we show that B-cell-specific constitutive activation of HH/GLI signaling either at the level of the HH effector and drug target Smoothened or at the level of the GLI transcription factors does not suffice to initiate a CLL-like phenotype characterized by the accumulation of CD5(+) B cells in the lymphatic system and peripheral blood. Furthermore, Hh/Gli activation in Pten-deficient B cells with activated Pi3K/Akt signaling failed to enhance the expansion of leukemic CD5(+) B cells, suggesting that genetic or epigenetic alterations leading to aberrant HH/GLI signaling in B cells do not suffice to elicit a CLL-like phenotype in mice. By contrast, we identify a critical role of GLI and PI3K signaling for the survival of human primary CLL cells. We show that combined targeting of GLI and PI3K/AKT/mTOR signaling can have a synergistic therapeutic effect in cells from a subgroup of CLL patients, thereby providing a basis for the evaluation of future combination therapies targeting HH/GLI and PI3K signaling in this common hematopoietic malignancy.
63
A mammalian protein targeted by G1-arresting rapamycin–receptor complex
Eric J. Brown, Mark W. Albers, Tae Bum Shin et al. · Nature · 1994 · 2.1K citations
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman, Jeff P. Sharman, Steven Coutré et al. · New England Journal of Medicine · 2014 · 1.7K citations · Full text
Vertebrate Smoothened functions at the primary cilium
Kevin C. Corbit, Pia Aanstad, Veena Singla et al. · Nature · 2005 · 1.5K citations
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Aleksandar Sekulić, Michael R. Migden, Anthony E. Oro et al. · New England Journal of Medicine · 2012 · 1.4K citations · Full text
Medicine, Oncology, Pharmacology +17